TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 905580
Drug: Oxytocin induction
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin induction (with or without estrogen pre‐treatment)
Study: 31881392
Drug: Cenicriviroc (CVC)
Normalized name: salicylic acid
DrugBank: Cenicriviroc (DB11758)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc (CVC) 150 mg orally once daily
Study: 30844878
Drug: BUP-XR 300/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-XR 300/300 mg
Study: 30844878
Drug: BUP-XR 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUP-XR 300/100 mg
Study: 21308781
Drug: Risperidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (20 patients, 3 mg daily)
Study: 21308781
Drug: Aripiprazole (21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (21 patients, 15 mg daily)
Study: 19363695
Drug: Carbohydrate beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate beverage (200 ml containing 12.5% maltodextrin) given 2 hours before operation
Study: 16222548
Drug: Levamisole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (2.5 mg/kg on alternate days for 1 year)
Study: 16222548
Drug: Control (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (low-dose prednisolone <0.5 mg/kg on alternate days for 1 year)
Study: 12734506
Drug: Tazarotene cream
Normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene cream 0.05%
Study: 9301382
Drug: Captopril 0.8‐0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 0.8‐0.9 mg kg‐1 orally, 45 min before induction of anaesthesia
Study: 9301382
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative medication)
Study: 8130356
Drug: Steroid-free immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-free immunosuppression (complete avoidance of steroids or withdrawal of steroids less than 3 months after transplantation)
Study: 8130356
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy (control group)
Study: 3481333
Drug: Ofloxacin 200mg
Normalized name: OFLOXACIN 200MG TAB
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin 200mg once daily
Study: 3481333
Drug: Norfloxacin 400mg
Normalized name: NORFLOXACIN 400MG TAB
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 400mg twice daily
Study: 31935146
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer laser (three times weekly for 8 weeks)
Study: 31520258
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture therapy
Study: 25876341
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of flunarizine hydrochloride capsules (5mg, once every night for 14 days)
Study: 25876341
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of flunarizine hydrochloride capsules
Study: 25876341
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture therapy and medicine group
Study: 21563952
Drug: Induction phase
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction phase (no oral hygiene for 21 days)
Study: 20463812
Drug: Azithromycin (a
Normalized name: azithromycin (as azithromycin dihydrate) 500 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (a macrolide antibiotic)
Study: 18677972
Drug: Suplatast tosilate
Normalized name: Edoxaban Tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suplatast tosilate (300 mg/day)
Study: 2005233
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel
Study: 2005233
Drug: 4% stannous
Normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% stannous fluoride gel
Study: 2005233
Drug: Amine fluoride
Normalized name: triethylene amine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride gel (1.25% fluoride)
Study: 326281
Drug: Diazepam 0.2
Normalized name: diazepam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.2 mg/kg
Study: 7046500
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 100 mg
Study: 31382932
Drug: Online Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Cognitive Behavioral Therapy (CBT)
Study: 29191450
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 1.1 mL (275 mg) of hydroxyprogesterone caproate (HPC) administered using an autoinjector
Study: 29191450
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 1 mL (250 mg) of hydroxyprogesterone caproate (HPC)
Study: 24210570
Drug: tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin 0.4 mg
Study: 24210570
Drug: alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfuzosin 10 mg
Study: 15500103
Drug: Acetated Ringer's
Normalized name: ACETATED RINGER'S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetated Ringer's solution (1,000 ml, n=8)
Study: 15500103
Drug: 6% hydroxyethylstarch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% hydroxyethylstarch (1,000 ml, n=9)
Study: 11474722
Drug: Mood-freezing pill
Normalized name: Freez Eez
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mood-freezing pill
Study: 9558806
Drug: Eclectic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eclectic treatment programs
Study: 9558806
Drug: Comprehensive clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive clinical treatment including hypnosis
Study: 3308390
Drug: Minaprine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minaprine (100 mg b.i.d.)
Study: 3308390
Drug: Imipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50 mg b.i.d.)
Study: 21812904
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg
Study: 25004024
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) in patients with pulmonary embolism
Study: 25004024
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) in patients without pulmonary embolism
Study: 11263272
Drug: Garlicin injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlicin injection (60 mg/day for 10 days)
Study: 8644686
Drug: Crackers with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crackers with cream cheese
Study: 8644686
Drug: Crackers with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crackers with nonfat cream cheese
Study: 6337669
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (medical measures, modified splenectomy, oesophagogastric devascularization)
Study: 20371056
Drug: Conventional Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Care (CC)
Study: 30566441
Drug: Supported Self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported Self-help Preventive Cognitive Therapy (S-PCT)
Study: 21515562
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (sequential and standard treatment)
Study: 14644054
Drug: Cognitive-behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral and family treatment components
Study: 14644054
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment approach
Study: 8884873
Drug: 4 IU/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IU/ml in a bicarbonate buffer dissolved in 0.9% benzyl alcohol (approximately 1.37 mg/ml)
Study: 8884873
Drug: 5.9 IU/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.9 IU/ml in a phosphate buffer dissolved in 1.5% benzyl alcohol (approximately 2 mg/ml)
Study: 8884873
Drug: 11.7 IU/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.7 IU/ml in a phosphate buffer dissolved in 1.5% benzyl alcohol (approximately 4 mg/ml)
Study: 8884873
Drug: 5.9 IU/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.9 IU/ml
Study: 8884873
Drug: 11.7 IU/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.7 IU/ml
Study: 8884873
Drug: 4 IU/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 IU/ml
Study: 1676318
Drug: Cabergoline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (1 mg, two 0.5 mg tablets and one placebo tablet within 27 hours after delivery, then placebo twice daily for 14 days)
Study: 1676318
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 mg, two placebo tablets within 27 hours after delivery, then 2.5 mg twice daily for 14 days)
Study: 18469148
Drug: Losartan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (2 microg/l)
Study: 17993594
Drug: Nitro-L-arginine (NLA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitro-L-arginine (NLA, 10 mM)
Study: 12601840
Drug: Both hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both hormone markers unaltered
Study: 8750077
Drug: Preference assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference assessment and simple, low‐effort treatment procedure
Study: 31776122
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term exposure to PM2.5 (1 µg/m3 increase)
Study: 29396118
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (feedback of screening results only)
Study: 27120082
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg single dose on the evening prior to surgery; 40 mg on the morning of surgery; three further doses of 40 mg on the evenings of postoperative days 0, 1, and 2)
Study: 23681396
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Placebo
Study: 22356933
Drug: Symbiotic shake
Normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic shake containing Lactobacillus acidophilus, Bifidobacterium bifidum, and fructooligosaccharides, 200 mL daily for 30 days.
Study: 22356933
Drug: Placebo shake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo shake without symbiotic bacteria, 200 mL daily for 30 days.
Study: 20606661
Drug: Certolizumab (biologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certolizumab (biologic therapy)
Study: 17256746
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) monotherapy (n = 14)
Study: 16398422
Drug: Integrated traditional
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated traditional and Western medicine (ITWM)
Study: 23275012
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM)
Study: 9526923
Drug: Quality assurance
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality assurance guidelines developed by the U.S. Food and Drug Administration and various dental specialties.
Study: 9526923
Drug: Clinical outcomes
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical outcomes of treatment and health and well-being measures.
Study: 9526923
Drug: Managed care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Managed care implications for quality of periodontal treatment and patient management.
Study: 19956980
Drug: Voriconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (400 mg i.v. every 12 h for two doses, followed by 300 mg BID)
Study: 19956980
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg i.v. twice daily for 2 days, followed by 200 mg i.v. daily)
Study: 19375108
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg pentosan polysulfate sodium per day
Study: 17343008
Drug: Yiqi Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Huoxue Recipe (YHR) combined with polyene phosphatidycholine capsule (PPC)
Study: 17343008
Drug: Polyene phosphatidycholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyene phosphatidycholine capsule (PPC) alone
Study: 16297506
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet plus two high-protein/energy supplements containing additional arginine (9 g), vitamin C (500 mg) and zinc (30 mg)
Study: 16297506
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet plus two high-protein/energy supplements
Study: 9842809
Drug: Succinylcholine (Sch)
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (Sch) 1.5 mg/kg
Study: 9842809
Drug: Rocuronium (Roc)
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium (Roc) 1.2 mg/kg
Study: 23864647
Drug: Phenytoin (184
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (184 mg once daily for 7 days post-delivery)
Study: 23864647
Drug: Control (zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/lamivudine at delivery and zidovudine/lamivudine for 7 days post-delivery)
Study: 21350434
Drug: Oral methylphenidate
Normalized name: methylphenidate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methylphenidate (MPH)
Study: 16809647
Drug: Water-soluble lubricant
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-soluble lubricant gel
Study: 16809647
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel (standard of care)
Study: 12518293
Drug: Ketamine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (bolus 0.23 mg/kg; 0.5 mg/kg over 45 min to a maximum 1 hr)
Study: 12020396
Drug: 5'‐DFUR administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5'‐DFUR administered orally for 6 months
Study: 16714187
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus dipyridamole
Study: 29882727
Drug: e-prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-prescription
Study: 26044464
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (150 kcal, 20 g whey protein, 800 IU vitamin D)
Study: 19565475
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg CP-690,550 twice daily
Study: 19565475
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg CP-690,550 twice daily
Study: 19565475
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg CP-690,550 twice daily
Study: 19565475
Drug: All CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: All CP-690,550 treatment arms
Study: 19565475
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg and 30 mg CP-690,550
Study: 15302243
Drug: Soft collar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft collar treatment for 3 weeks followed by the same exercise regime
Study: 9436283
Drug: Non-T1c tumors
Normalized name: HUMAN BREAST TUMOR CELL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-T1c tumors with PSA < 4 ng/ml
Study: 27501614
Drug: Intra-Articular Infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-Articular Infiltration (IA) with 15 mL of 0.25% bupivacaine into the knee joint and 5 mL infiltrated along the incision sites.
Study: 27501614
Drug: Femoral Nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral Nerve Block (FNB) with 20 mL of 0.25% bupivacaine under ultrasound guidance.
Study: 24853809
Drug: Insulin only
Normalized name: Isophane insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin only (32%)
Study: 24853809
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and oral antidiabetics (OADs) (15%)
Study: 24853809
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs (26%)
Study: 23011325
Drug: Calcium‐containing preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium‐containing preparation administrated orally for 1 to 3 months
Study: 20498618
Drug: Valsartan/hydrochlorothiazide (320/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/hydrochlorothiazide (320/25 mg)
Study: 20498618
Drug: Hydrochlorothiazide plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide plus amlodipine (25 mg and 10 mg)
Study: 18677236
Drug: Moderate viscosity
Normalized name: polyethylene terephthalate (intrinsic viscosity 0.40-0.70)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate viscosity hydroxypropylmethylcellulose-containing formulation
Study: 10100273
Drug: Liposomal daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal daunorubicin (DaunoXome) - 60 mg/m2, intravenous infusion, once every 4 weeks, up to 600 mg/m2 cumulative dose
Study: 1672392
Drug: Intramuscular magnesium
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular magnesium sulphate every week for 6 weeks
Study: 6512802
Drug: Intravenous Augmentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Augmentin (amoxycillin and clavulanic acid)
Study: 30475777
Drug: Esophageal pressure
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esophageal pressure titration PEEP (n = 12)
Study: 30475777
Drug: ARDSNet (PEEP-FiO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARDSNet (PEEP-FiO2 table) titration PEEP (n = 11)
Study: 29480843
Drug: Early rehabilitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rehabilitation therapy
Study: 26973269
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rehabilitation therapy after leaving ICU)
Study: 24738933
Drug: Vitamin B1
Normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B1 100 mg daily for three months
Study: 22343669
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) during HSCT
Study: 15257032
Drug: FK778 high-level
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK778 high-level group (2 x 600 mg/day FK778 followed by 150 mg/day)
Study: 15257032
Drug: FK778 low-level
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FK778 low-level group (1 x 600 mg/day FK778 followed by 75 mg/day)
Study: 15257032
Drug: FK778 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FK778 treatment
Study: 9851959
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 mg administered intravenously)
Study: 2692315
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ASS daily
Study: 2692315
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ASS daily
Study: 31284771
Drug: Mirogabalin 15
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 15 mg twice daily
Study: 31722446
Drug: Mirogabalin 10
Normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Mirogabalin 10 or 15 mg twice daily
Study: 31004141
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) plus 48-hour positive airway pressure (PAP) therapy
Study: 20920136
Drug: Spray catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray catheter instillation
Study: 20920136
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection through the working channel
Study: 10613619
Drug: Acetaminophen plus
Normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen plus codeine
Study: 9605375
Drug: Oxycodone 30
Normalized name: oxycodone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 30 microg/kg
Study: 9605375
Drug: Morphine 45
Normalized name: morphine 45 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 45 microg/kg
Study: 8091435
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL)
Study: 8091435
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL) in normotensive subjects
Study: 8091435
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL) in men 60 years or younger
Study: 3053207
Drug: cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin 100 mg/m2 with cyclophosphamide 600 mg/m2